Tarsus Pharmaceuticals (TARS) Share-based Compensation (2020 - 2026)

Tarsus Pharmaceuticals' Share-based Compensation history runs 7 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 72.68% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $15.2 million (down 55.63% YoY), while the FY2025 annual figure was $10.2 million, down 63.3% from the prior year.
• Share-based Compensation for Q1 2026 stood at $12.0 million, up from -$5.0 million in the prior quarter.
• The five-year high for Share-based Compensation was $20.0 million in Q3 2024, with the low at -$12.5 million in Q4 2023.
• The 5-year median for Share-based Compensation is $3.7 million (2022), against an average of $4.4 million.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation soared 4677.33% in 2022, then plunged 440.56% in 2023.
• Tarsus Pharmaceuticals' Share-based Compensation stood at $3.7 million in 2022, then slumped by 440.56% to -$12.5 million in 2023, then soared by 159.21% to $7.4 million in 2024, then plunged by 166.92% to -$5.0 million in 2025, then jumped by 341.56% to $12.0 million in 2026.
• Business Quant data shows TARS's Share-based Compensation at $12.0 million in Q1 2026, -$5.0 million in Q3 2025, and $8.2 million in Q2 2025.